Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
about
The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglyceridesEffects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic miceEndocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor familiesBile acid nuclear receptor FXR and digestive system diseasesAPOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levelsIs apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean populationThe association between APOA5 haplotypes and plasma lipids is not modified by energy or fat intake: the Czech HAPIEE studyGenetic Variants Associated with Gestational Hypertriglyceridemia and PancreatitisThyroid hormone regulates the hypotriglyceridemic gene APOA5The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormoneWild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cellsGlycosylphosphatidylinositol-specific phospholipase D influences triglyceride-rich lipoprotein metabolismLupin protein influences the expression of hepatic genes involved in fatty acid synthesis and triacylglycerol hydrolysis of adult rats.The C terminus of apolipoprotein A-V modulates lipid-binding activity.Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene - 1131T>C variant and associations with plasma lipids and lipid peroxidation.Apolipoprotein A5 and lipoprotein lipase interact to modulate anthropometric measures in Hispanics of Caribbean origin.Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor.Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.Synthesis analysis of regression models with a continuous outcomeBiogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion.A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout miceStudies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approachApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content.Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula miceLipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humansIncreased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects.Transcriptome Analysis Reveals Regulation of Gene Expression for Lipid Catabolism in Young Broilers by Butyrate Glycerides.APOA5 genotype modulates 2-y changes in lipid profile in response to weight-loss diet intervention: the Pounds Lost TrialGive me A5 for lipoprotein hydrolysis!Genetics of non-conventional lipoprotein fractions.Apolipoprotein A-V is present in bile and its secretion increases with lipid absorption in Sprague-Dawley ratsDeterminants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiencyRegulation of postprandial lipemia: an update on current trends.Genotype-specific weight loss treatment advice: how close are we?Association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with susceptibility to myocardial infarction in MoroccoOverexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis.
P2860
0cfd5f4820fdb74cec7e27b610bb720136c449d132f75cb3ae46eb978ef8dfa0d2c712587d0566936b03564cc3dadf777f9cba04bd78320c26b0ca09d913ab14ca858688a8b3b5de175ff791373826a0e3f2bd6fa5b0aa8c1388e0c9191737bbdbcbe77ee99acf910afdf66682c47d523759d4cc497bd48cead3d7eee09552e8ce6a9dd638055fc6350fe47bf50000eb47138d4d5b2d6db58b1332f11d1869cd
P248
Q21261422-418C206C-2CB6-4799-A333-0025E46ED0F2Q24302828-76D5696C-570A-42D0-80BC-F2631ECE895BQ24651670-0A2D344D-A92E-4F78-9884-B2A738AA92EFQ28085493-31473FA4-B41F-47D1-A859-83AC16DC3A31Q28286099-9884BAE1-E1D3-49ED-922C-26828FC6545FQ28294769-76FBA822-FF07-410D-86B6-0910A075B893Q28302513-B8AF1759-D374-4BEF-A738-3EE4F19BC670Q28306572-CF42B4EB-57F2-46E6-9EFD-FA82E7DE221AQ28548394-1E84A143-2350-412D-8952-1AFF3C2A7C4BQ28569807-9A440199-ACF3-4739-BE85-76855F2BCEB5Q28579695-11DC1F6A-7A35-41F2-9272-BFE8DCBDF05DQ28585300-87B93253-5800-4507-A6BA-F84C4BD2100EQ28593575-9B5549D0-E9C1-442F-B8C9-95D82A71A25AQ30319700-B0F58278-A295-4042-88F8-C6BECCACA52FQ30360807-DDD47441-75A6-4DD0-8C7B-15735F99E68BQ33293923-F65D951E-DAE6-4AB0-ABC1-F09A4FA228D0Q33620859-6E68B032-FFFB-4209-835A-7F9418DC59F0Q33727061-85E0BED9-30B2-4350-8CAA-A1783964FB48Q33823946-D32B2F85-72B9-4B88-AAE2-999BC16B67D8Q34048473-730758FA-75F0-4D52-9347-6D3AFB45E12BQ34189395-2D0034C6-789C-43C3-B9BD-89EDCC028A7AQ34503351-47938DE9-8FDF-4C69-9C94-E8F3555A85B3Q34946523-D199930F-19E7-4009-B3A2-93D82B2DF90AQ35104849-E2C67F22-1C3E-457C-BE0E-52AE710BA82AQ35120896-D354532F-AB3B-445E-B155-D5AA35474869Q35274124-BE5AD8B2-9DF5-4657-9F84-B06571C24A1BQ35559092-05C21D24-5838-49F7-AF54-A80D1EF55882Q35592272-3B044242-445F-42D5-B575-30E7F409CFD0Q36054819-1D509347-EB5A-495D-9AF1-F46D09A76958Q36100254-5277E26D-EB7A-47E1-B3A8-F0AF49BCB898Q36231656-BF26DBDA-EDF6-49D4-987D-32653AA33A44Q36274976-06470D21-832C-4C5C-BBBE-700C1EB2E59BQ36317025-B1AD1104-DAF7-4555-AB58-46D00751FB21Q36345922-FE881FDA-A160-429A-B2AE-40FE387B3FDDQ36496770-3C45501F-8860-4527-8A3C-AB4038BF6F92Q36558367-DEB5C5DE-38D4-4A02-B7E3-51B3CD860D68Q36749246-1FC59C94-58FC-4022-A065-9EE756DAD256Q36825609-2D47A048-C946-4959-9CC8-C335CD060BC0Q36870194-257A9D58-0052-4DE6-853B-239488D4DD54Q37209161-EAF07702-4E70-46B6-B13D-583E971FF618
P2860
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@ast
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@en
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@en-gb
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@nl
type
label
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@ast
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@en
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@en-gb
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@nl
prefLabel
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@ast
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@en
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@en-gb
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@nl
P2093
P921
P3181
P1476
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
@en
P2093
Benoit Thomas
Bryan Brewer
Corinne Rommens
Jamila Fruchart-Najib
Jean-Charles Fruchart
Len A Pennacchio
Tatiana Pham
Zouher Majd
P304
P3181
P356
10.1016/J.BBRC.2004.05.003
P407
P577
2004-06-01T00:00:00Z